For example, loss of PDCD4 expression was correlated with poor patient prognosis, higher tumor grade and stage in lung cancers [8], shorter disease-free survival of ovarian cancer patients [25], as well as with clinicopathological features of tumor aggressiveness (e.g., nodal metastasis, advanced tumor stage) in gastric cancer [26]. Here, PDCD4 is linked to gastric cancer.